Two "Zibo Pharmaceuticals" selected seventh batch of national drug collection

□ Zibo Daily/Zibo Evening News/Expo News

Reporter Chang Xu Correspondent Liu Lulu

On July 12, under the organization and guidance of relevant departments such as the National Medical Insurance Bureau, the seventh batch of centralized procurement of drugs organized in Nanjing, Jiangsu, was generated in Nanjing, Jiangsu. Two drugs produced by Xinhua Pharmaceuticals in our city stand out and successfully elected.

The national collection competition was fierce. A total of 488 products from 295 companies participated in the bidding, and the 327 products of 217 companies were qualified for the selection. Among them, 6 of the six international pharmaceutical companies were selected, and 211 domestic pharmaceutical companies were selected, and the supply of diversification and stability was further enhanced.

In this collection, Xinhua Pharmaceuticals achieved two specifications of two medicines, namely Donald (pyloglidone capsules) and pyropistic (icolinin phosphate injection). Among them, the selected price of 15mg*60 tablets/box of pylllitone capsules of hydrochloride is 16.17 yuan, and 9 provinces in the selection areas are Guangdong Province, Jiangsu Province, Shandong Province, Anhui, Guangxi Province, Hunan Province, Xinjiang, Qinghai Province, and Qinghai Province, and Qinghai Province. Gansu Province; Klimrin phosphate injection of 0.3g/branch is 0.835 yuan, and the selection price of 0.6g/branch is 1.4295 yuan. The selection area is Hubei, Shanghai, and Fujian Province. It is worth noting that the pioglidone capsules produced by Xinhua Pharmaceuticals are the first election in the first order, which can select the maximum purchase volume. It is estimated that the sales of the drug will increase from 14 million pieces before the selection to 110 million pieces, an increase of nearly 8 times.

This collection is the first national collection of drug collection in 2022. There are 60 drugs for procurement. The average price reduction of drugs is planned to be reduced by 48%. According to the agreed purchase volume, it is expected to save 18.5 billion yuan per year. The selected drugs involved 31 treatment categories, including common diseases such as hypertension, diabetes, anti -infection, digestive tract diseases, and major diseases such as lung cancer, liver cancer, kidney cancer, and bowel cancer. Essence It is expected that patients across the country will use the selected drugs after this collection of prices in November 2022.

In recent years, the city has accumulated mature "Zibo experience" in centralized procurement. The joint procurement office of Shandong Pharmaceutical and Medical Coodles is located in the Zibo Medical Security Bureau. While successfully organizing many provincial -level collection and continuous procurement activities, the Municipal Medical Security Bureau actively played the role of bridge and bonds, and held many high -quality development symposiums and training meetings to help pharmaceuticals and weapon enterprises. Adopting policies and normalization and institutionalized development trends, improving the ability of local pharmaceutical companies to respond to new situations, and fully help the Zibo pharmaceutical industry to achieve high -quality development.

- END -